1. Characteristics, treatment patterns and disease burden of people with Parkinson's disease in the Parkinson's disease real-world impact assessment (PRISM) study. (October 2020) Authors: Foltynie, T.; Tolosa, E.; Ferreira, J.J.; Antonini, A.; Lees, A.; Ebersbach, G.; Rascol, O.; Rocha, J.-F.; Magalhães, D.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations. (October 2020) Authors: Lees, A.; Ferreira, J.J.; Poewe, W.; Gama, H.; Magalhães, D.; Rocha, J.-F.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy of opicapone in Parkinson's patients with motor fluctuations and ON Hoehn & Yahr ≤2.5: post hoc analysis of BIPARK-1. (October 2020) Authors: Lew, M.F.; Hauser, R.A.; Isaacson, S.; Ferreira, J.J.; Serbin, M.; Farahmand, K.; Olson, K.; Klepitskaya, O.; Rocha, F.; Soares-da-Silva, P.; Liang, G.S. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II. (October 2020) Authors: Rascol, O.; Poewe, W.; Ferreira, J.J.; Lees, A.; Santos, A.-T.; Magalhães, D.; Rocha, J.F.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson's disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. (October 2020) Authors: Ferreira, J.J.; Lees, A.; Ebersbach, G.; Santos, A.; Magalhães, D.; Rocha, J.-F.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy/safety of opicapone in Parkinson's disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II. (October 2020) Authors: Ebersbach, G.; Rascol, O.; Ferreira, J.J.; Costa, R.; Rocha, J.F.; Magalhães, D.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses. (October 2020) Authors: Hauser, R.A.; Lew, M.F.; Comella, C.L.; Poewe, W.; Rascol, O.; Ferreira, J.J.; Olson, K.; Farahmand, K.; Shah, C.; Rocha, J.-F.; Soares-da-Silva, P.; Klepitskaya, O. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OFF/-ON-time changes after switching from entacapone or placebo to opicapone in patients ending the BIPARK-I extension study on opicapone 50-mg. (October 2020) Authors: Poewe, W.; Ferreira, J.J.; Lees, A.; Rascol, O.; Ikedo, F.; Magalhães, D.; Rocha, J.-F.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Opicapone as first-line adjunctive levodopa treatment in Parkinson's disease patients with motor fluctuations: BIPARK-I and II combined post-hoc analysis. (October 2020) Authors: Ferreira, J.J.; Poewe, W.; Antonini, A.; Gama, H.; Rocha, J.F.; Magalhães, D.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Opicapone's added benefit as a first-line adjunctive therapy to levodopa and when used promptly for motor fluctuations in Parkinson's disease. (October 2020) Authors: Ebersbach, G.; Ferreira, J.J.; Antonini, A.; Santos, A.; Magalhães, D.; Rocha, J.-F.; Soares-da-Silva, P. Journal: Parkinsonism & related disorders Issue: Volume 79(2020) Supplement 1 Page Start: e71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗